A 62-Year-Old Woman With Epithelioid Sarcoma Treated With Tazemetostat
Panelists discuss how a real-world case of epithelioid sarcoma (ES) highlights the critical role of early recognition, comprehensive diagnostics including INI1 testing, and a multidisciplinary approach to personalize treatment based on disease extent, tumor location, and molecular features.
Summary for Physicians: Case-Based Discussion in ES
A patient case was presented to illustrate the complexities of diagnosing and managing ES. The case highlighted the importance of early recognition, thorough diagnostic workup—including imaging and histopathologic evaluation—and the role of molecular testing (eg, INI1 loss) in confirming the diagnosis.
Initial impressions from the group emphasized the diagnostic challenges, particularly when ES mimics benign or inflammatory conditions. Participants noted the importance of maintaining a broad differential in atypical soft tissue masses and the utility of early biopsy and referral to a specialized sarcoma center.
In terms of treatment, discussion focused on tailoring the approach based on disease extent, tumor location, patient status, and molecular characteristics. Surgery was considered central for localized disease, while systemic therapy was emphasized in cases with advanced or metastatic features. The case underscored the need for a multidisciplinary strategy and highlighted how evolving molecular insights may guide more personalized treatment decisions in clinical practice.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
